Everolimus in clinical practice in long-term liver transplantation: An observational study

Transplantation Proceedings

Volumn 43, Issue 6, 2011, Pages 2216-2219

  Casanovas, T ^a   Argudo, A ^a   Pena Cala M C ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSPORIN; EVEROLIMUS; GAMMA GLUTAMYLTRANSFERASE; PREDNISONE; TACROLIMUS; UREA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKOPENIA; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MONOTHERAPY; NEUROTOXICITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; UREA BLOOD LEVEL;

AGED; CALCINEURIN; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; SPAIN; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 80051704548     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.06.015     Document Type: Article

References (31)

1. J. Fung, D. Kelly, and Z. Kadry Immunosuppression in liver transplantation: beyond calcineurin inhibitors Liver Transpl 11 2005 267
2. S. Iacob, V.R. Cicinnati, and S. Beckebaum Current immunosuppressive approaches in liver transplantation Panminerva Med 51 2009 215
3. J.F. Castroagudín, E. Molina, and R. Romero Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction Liver Transpl 15 2009 1792
4. P. De Simone, H.J. Metselaar, and L. Fischer Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial Liver Transpl 15 2009 1262
5. K. Budde, H.H. Neumayer, and G. Lehne Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients Nephrol Dial Transplant 19 2004 2606
6. J.F. Delgado, N. Manito, and J. Segovia The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation Transplant Rev (Orlando) 23 2009 69
7. G. Levy, H. Schmidli, and J. Punch Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12-and 36-month results Liver Transpl 12 2006 1640
8. M. Majewski, M. Korecka, and J. Joergensen Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses Transplantation 75 2003 1710
9. S. Bhoori, S. Toffanin, and C. Sposito Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle J Hepatol 52 2010 771
10. C. Toso, S. Merani, and D.L. Bigam Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma Hepatology 51 2010 1237
11. G.I. Kirchner, I. Meier-Wiedenbach, and M.P. Manns Clinical pharmacokinetics of everolimus Clin Pharmacokinet 43 2004 83
12. N. Weiler, I. Thrun, and M. Hoppe-Lotichius Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial Transplantation 90 2010 1562
13. K. Budde, T. Becker, W. Arns ZEUS Study Investigators Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial Lancet 377 2011 837
14. D.R. Kuypers Influence of interactions betwen immunosuppressive drugs on therapeutic drug monitoring Ann Transpl 13 2008 11
15. J.M. Kovarik, H.D. Sabia, and I. Figuereido Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment Clin Pharmacol Ther 70 2001 425
16. S.M. Flechner, J. Kobashigawa, and G. Klintmalm Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity Clin Transplant 22 2008 1
17. H. Holdaas, O. Bentdal, and P. Pfeffer Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study Clin Transplant 22 2008 366
18. P. De Simone, P. Carrai, and A. Precisi Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function Transpl Int 22 2009 279
19. D. Wagner, D. Kniepeiss, and S. Schaffellner Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates Int Immunopharmacol 10 2010 990
20. L. Merli, F. Gentili, and M. Giusto Immune liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? Dig Liver Dis 41 2009 345
21. J. Dantal, F. Berthoux, and M.Ch. Moal Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial Transpl Intern 23 2010 1084
22. L. Lladó, J. Fabregat, J. Castellote THOSIN Study Group Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study Liver Transpl 14 2008 1752
23. B.V. Maramattom, and E.F. Wijdicks Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients Neurology 63 2004 1958
24. S. Asthana, C. Toso, and G. Meeberg The impact of sirolimus on hepatitis C recurrence after liver transplantation Can J Gastroenterol 25 2011 28
25. J. Gomez-Camarero, M. Salcedo, and D. Ricon Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms Transplantation 84 2007 786
26. A. Gutierrez-Dalmau, and J.M. Campistol Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review Drugs 67 2007 1167
27. J. Pascual, A.M. Fernández, and R. Marcén Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia-a case report Nephrol Dial Transplant 21 suppl 3 2006 iii 38
28. V. Sparacino, and S. Calabrese Conversion to a proliferation signal inhibitor in a patient with coronary artery disease-a case report Nephrol Dial Transplant 21 suppl 3 2006 iii 34
29. J.M. Kovarik, H. Tedesco, and J. Pascual Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation Ther Drug Monit 26 2004 499
30. J. Campsen, M.A. Zimmerman, and J.F. Trotter Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal Liver Transpl 14 2008 1281
31. J.I. Herrero, J.I. Herrero, and F. Alegre Usefulness of a program of neoplasia surveillance in liver transplantation A preliminary report Clin Transplant 23 2009 532